Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hemay 007

Next Previous
Search
Drug Profile

Hemay 007

Alternative Names: Hemay-007

Latest Information Update: 11 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hemay Pharmaceutical
  • Developer Hemay Pharmaceutical; Tianjin Hemay Pharmaceutical Sci-Tech
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis; Ulcerative colitis
  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 12 Aug 2022 Tianjin Hemay Pharmaceutical terminates a phase II trial in Ulcerative colitis in China (PO), due to the difficulty to recruit enough patients (NCT03977480)
  • 26 Mar 2021 Phase-II clinical trials in Rheumatoid arthritis (Treatment-experienced) in China (PO) (NCT05247216)
  • 28 Jan 2020 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases(In volunteers) in Australia (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top